FAKTOR-OPTIONSSCHEIN - INCYTE CO. Stock

DE000MG0JZQ1

Market Closed - Börse Stuttgart 02:50:30 2024-06-07 pm EDT
10.12 ^EUR	+3.48%

Current month	+4.87%
1 month	+16.86%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart INCYTE CORPORATION

Latest news about INCYTE CORPORATION

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	Jun. 07	BU
Incyte Completes Acquisition of Escient Pharmaceuticals	May. 30	BU
Deutsche Bank Initiates Incyte to Hold Rating With $55 Price Target	May. 23	MT
Incyte Acquires 2 Office Buildings in Delaware	May. 21	MT

More news

Quotes 5-day view

Date	Price	Change
24-06-07	10.12	+3.48%
24-06-06	9.78	-2.30%
24-06-05	10.01	+1.42%
24-06-04	9.87	-0.70%
24-06-03	9.94	+3.01%

Delayed Quote Börse Stuttgart

Last update June 07, 2024 at 02:50 pm EDT

More quotes

Static data

Product type	Exotic Products
Buy / Sell	CALL
Underlying	INCYTE CORPORATION
Issuer	Morgan Stanley
WKN	MG0JZQ
ISIN	DE000MG0JZQ1
Date issued	2024-03-20
Strike	29.21 $
Maturity	Unlimited
Parity	2.74 : 1
Emission price	10 €
Emission volume	N/A
Settlement	cash
Currency	EUR

Technical Indicators

Highest since issue	10.13 €
Lowest since issue	7.56 €
Spread	0.02 €
Spread %	0.20%

Company Profile

Incyte Corporation specializes in the research & development of therapeutic products mainly intended for the treatment of cancers and inflammatory disorders. Net sales break down by revenue source as follows: - product sales (85.6%); - royalties (14.2%); - income from research and cooperation agreements (0.2%).

Sector

More about the company

Ratings for Incyte Corporation

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Consensus: Incyte Corporation

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

59.16 USD

Average target price

72.8 USD

Spread / Average Target

+23.06%

Consensus